#96FUZKK atlas leaders 1–100

EVA Pharma

Egypt · Africa

Diversified pharma

Manufacturing profile

Diversified pharma

Country: Egypt

Macro-region: Africa

Selection basis

The company is placed in positions 1–100 as a major manufacturer, biopharmaceutical group, generics/API/CDMO leader or a significant regional manufacturing participant.

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Representative manufacturing and QC chain

1Portfolio of products and manufacturing sites
2Multiple manufacturing process types
3Shared supplier, validation and data controls
4Product-specific and instrumental QC
5Group QMS, release and lifecycle evidence

Relevant FUZKK packages

China: national essential medicines QC package Lumex QC Suite LabEx QC Suite Medical Device QMS Suite

Product/API utilities

Assay & Impurities Result Reviewer

Lumex — instrumental QC

Genotoxic Impurity Screener M7 Content Uniformity Acceptance Value System Suitability Parameters Checker

LabEx — laboratory QC

Assay & Impurity HPLC Quality Checker Residual Solvents GC Quality Checker Water Content KF Quality Checker

Medical Devices — equipment and software lifecycle

Release Readiness Checker Supplier Evaluation Checker Calibration Status Checker Process Validation Checker Change Control Impact Checker Data Integrity Security Checker Requirement Traceability Checker

Suggested first pilot

Confirm one real product, method or recurring QC review.
Record the instrument, export format and current specification.
Select 3–7 utilities from the map above.
Run a PASS/FAIL sample and agree the expected output.
After user validation, expand to other products and sites.

Mapping boundary

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Methodology